Regentis Biomaterials Ltd. (RGNT) Stock Price
RGNTStock
$1.49
Market Cap$10.47M
P/E—
PEG Ratio—
Div yield—
Beta—
RGNT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-60.89%
Price vs S&P 500 (4W)-31.86%
VGM Score23.13
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
RGNTRegentis Biomaterials Ltd. | — | — | D | — | — | — | — | $1.49 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
About Regentis Biomaterials Ltd.
Regentis Biomaterials develops regenerative medicine solutions for orthopedic tissue repair. Its lead product, GelrinC, is a cell-free hydrogel implant designed to treat cartilage injuries in the knee, based on the company's proprietary Gelrin platform. The company targets the significant market opportunity in orthopedic regenerative medicine.